Indeed, expression profiling of a subset of tumor types, such as clear cell renal cell carcinoma (ccRCC) and colorectal cancer, has recently proposed the expression level of EFHD1 as a prognostic factor and biomarker (Meng et al, 2023). Here, EFHD1 is linked to neoplasm.